RECURRENT OVARIAN HIGH GRADE SEROUS ADENOCARCINOMA
Clinical trials for RECURRENT OVARIAN HIGH GRADE SEROUS ADENOCARCINOMA explained in plain language.
Never miss a new study
Get alerted when new RECURRENT OVARIAN HIGH GRADE SEROUS ADENOCARCINOMA trials appear
Sign up with your email to follow new studies for RECURRENT OVARIAN HIGH GRADE SEROUS ADENOCARCINOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New Two-Punch combo tested for Tough-to-Treat ovarian cancer
Disease control Recruiting nowThis early-phase study is testing the safety and best dose of two oral drugs, abemaciclib and olaparib, given together for ovarian cancer that has returned and is resistant to standard platinum-based chemotherapy. The goal is to see if combining these drugs, which work in differe…
Matched conditions: RECURRENT OVARIAN HIGH GRADE SEROUS ADENOCARCINOMA
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Mar 27, 2026 12:38 UTC
-
New pill targets tough cancers in early safety trial
Disease control Recruiting nowThis is a first-in-human study to find a safe dose of a new oral drug called IACS-6274. It will be tested alone and in two different drug combinations in adults with advanced solid tumors that have stopped responding to standard treatments. The main goals are to check the safety …
Matched conditions: RECURRENT OVARIAN HIGH GRADE SEROUS ADENOCARCINOMA
Phase: PHASE1 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Mar 24, 2026 12:03 UTC
-
Scientists test new drug duo to target Tough-to-Treat gynecologic cancers
Disease control Recruiting nowThis early-stage study is testing a new combination of two oral drugs, M1774 and ZEN-3694, for women with recurrent ovarian or endometrial cancer. The main goals are to find the safest and most effective dose and to see how well the drugs work together to stop cancer cell growth.…
Matched conditions: RECURRENT OVARIAN HIGH GRADE SEROUS ADENOCARCINOMA
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Mar 23, 2026 15:18 UTC